Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Beam Therapeutics sublicenses Editas' gene editing technologies

Executive Summary

Recently founded Beam Therapeutics Inc. sublicensed exclusive rights to intellectual property related to various genome editing technologies Editas Medicine Inc. had gained through previous deals with Harvard University, the Broad Institute, and Massachusetts General Hospital. Beam also signed a concurrent deal with the Broad Institute, Harvard, and MIT for additional base editing platforms.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register